191 related articles for article (PubMed ID: 35746897)
21. IgG and leukocytes: Targets of immunomodulatory α2,6 sialic acids.
Jones MB
Cell Immunol; 2018 Nov; 333():58-64. PubMed ID: 29685495
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of sialoglycopolypeptide for potentially blocking influenza virus infection using a rat alpha2,6-sialyltransferase expressed in BmNPV bacmid-injected silkworm larvae.
Ogata M; Nakajima M; Kato T; Obara T; Yagi H; Kato K; Usui T; Park EY
BMC Biotechnol; 2009 Jun; 9():54. PubMed ID: 19500344
[TBL] [Abstract][Full Text] [Related]
23. α2,6 Sialylation mediated by ST6GAL1 promotes glioblastoma growth.
Gc S; Tuy K; Rickenbacker L; Jones R; Chakraborty A; Miller CR; Beierle EA; Hanumanthu VS; Tran AN; Mobley JA; Bellis SL; Hjelmeland AB
JCI Insight; 2022 Nov; 7(21):. PubMed ID: 36345944
[TBL] [Abstract][Full Text] [Related]
24. Impact of Fc N-glycan sialylation on IgG structure.
Zhang Z; Shah B; Richardson J
MAbs; 2019; 11(8):1381-1390. PubMed ID: 31411531
[TBL] [Abstract][Full Text] [Related]
25. β-Galactoside α2,6-sialyltranferase 1 promotes transforming growth factor-β-mediated epithelial-mesenchymal transition.
Lu J; Isaji T; Im S; Fukuda T; Hashii N; Takakura D; Kawasaki N; Gu J
J Biol Chem; 2014 Dec; 289(50):34627-41. PubMed ID: 25344606
[TBL] [Abstract][Full Text] [Related]
26. Deficiency in ST6GAL1, one of the two α2,6-sialyltransferases, has only a minor effect on the pathogenesis of prion disease.
Makarava N; Katorcha E; Chang JC; Lau JTY; Baskakov IV
Front Mol Biosci; 2022; 9():1058602. PubMed ID: 36452458
[TBL] [Abstract][Full Text] [Related]
27. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone.
Hodgson K; Orozco-Moreno M; Goode EA; Fisher M; Garnham R; Beatson R; Turner H; Livermore K; Zhou Y; Wilson L; Visser EA; Pijnenborg JF; Eerden N; Moons SJ; Rossing E; Hysenaj G; Krishna R; Peng Z; Nangkana KP; Schmidt EN; Duxfield A; Dennis EP; Heer R; Lawson MA; Macauley M; Elliott DJ; Büll C; Scott E; Boltje TJ; Drake RR; Wang N; Munkley J
EBioMedicine; 2024 Jun; 104():105163. PubMed ID: 38772281
[TBL] [Abstract][Full Text] [Related]
28. Response to Oswald et al.: ST6Gal1 in plasma is dispensable for IgG sialylation.
Werner A; Nimmerjahn F
Glycobiology; 2022 Oct; 32(11):917-918. PubMed ID: 36036830
[TBL] [Abstract][Full Text] [Related]
29. Glycomics reveal that ST6GAL1-mediated sialylation regulates uterine lumen closure during implantation.
Han K; Wang F; Yue Y; Tan X; Tian M; Miao Y; Zhao S; Dong W; Yu M
Cell Prolif; 2022 Jan; 55(1):e13169. PubMed ID: 34957619
[TBL] [Abstract][Full Text] [Related]
30. Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G.
Ogata S; Shimizu C; Franco A; Touma R; Kanegaye JT; Choudhury BP; Naidu NN; Kanda Y; Hoang LT; Hibberd ML; Tremoulet AH; Varki A; Burns JC
PLoS One; 2013; 8(12):e81448. PubMed ID: 24324693
[TBL] [Abstract][Full Text] [Related]
31. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D
PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936
[TBL] [Abstract][Full Text] [Related]
32. ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab.
Duarte HO; Rodrigues JG; Gomes C; Hensbergen PJ; Ederveen ALH; de Ru AH; Mereiter S; Polónia A; Fernandes E; Ferreira JA; van Veelen PA; Santos LL; Wuhrer M; Gomes J; Reis CA
Oncogene; 2021 May; 40(21):3719-3733. PubMed ID: 33947960
[TBL] [Abstract][Full Text] [Related]
33. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA
Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896
[TBL] [Abstract][Full Text] [Related]
34. Production of α2,6-sialylated IgG1 in CHO cells.
Raymond C; Robotham A; Spearman M; Butler M; Kelly J; Durocher Y
MAbs; 2015; 7(3):571-83. PubMed ID: 25875452
[TBL] [Abstract][Full Text] [Related]
35. Sialylation of MUC4β N-glycans by ST6GAL1 orchestrates human airway epithelial cell differentiation associated with type-2 inflammation.
Zhou X; Kinlough CL; Hughey RP; Jin M; Inoue H; Etling E; Modena BD; Kaminski N; Bleecker ER; Meyers DA; Jarjour NN; Trudeau JB; Holguin F; Ray A; Wenzel SE
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30730306
[TBL] [Abstract][Full Text] [Related]
36. Modulating IgG effector function by Fc glycan engineering.
Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
[TBL] [Abstract][Full Text] [Related]
37. Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations
Schaffert A; Hanić M; Novokmet M; Zaytseva O; Krištić J; Lux A; Nitschke L; Peipp M; Pezer M; Hennig R; Rapp E; Lauc G; Nimmerjahn F
Front Immunol; 2019; 10():3024. PubMed ID: 31998308
[TBL] [Abstract][Full Text] [Related]
38. Impact of sialyltransferase ST6GAL1 overexpression on different colon cancer cell types.
Venturi G; Gomes Ferreira I; Pucci M; Ferracin M; Malagolini N; Chiricolo M; Dall'Olio F
Glycobiology; 2019 Sep; 29(10):684-695. PubMed ID: 31317190
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of alpha2,6 sialylation during myeloid maturation: a potential role in myeloid cell release from the bone marrow.
Le Marer N; Skacel PO
J Cell Physiol; 1999 Jun; 179(3):315-24. PubMed ID: 10228950
[TBL] [Abstract][Full Text] [Related]
40. Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics.
Ankenbauer KE; Rao TC; Mattheyses AL; Bellis SL
J Biol Chem; 2023 Oct; 299(10):105217. PubMed ID: 37660914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
